Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Atea Pharmaceuticals, Inc. publishes a filing, an earnings call transcript or a press release.

Get AVIR alerts

About Andrea Corcoran

Andrea Corcoran is recorded as CFO at Atea Pharmaceuticals, Inc. (AVIR). The newest filing on record that lists Andrea Corcoran as CFO at Atea Pharmaceuticals, Inc. (AVIR) is dated April 27, 2026. The proxy statement of Atea Pharmaceuticals, Inc. reports total compensation of $1,690,428 for Andrea Corcoran in fiscal 2025, including a base salary of $549,530. Disclosed compensation is on record for 7 fiscal years. Andrea Corcoran has spoken on 21 earnings calls across 1 company, most recently for Atea Pharmaceuticals, Inc. on November 9, 2026. Atea Pharmaceuticals, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Atea Pharmaceuticals, Inc. includes Jean-Pierre Sommadossi (CEO and Board Member), Wayne Foster (Chief Accounting Officer), Arthur Kirsch (Board Member) and 7 others.

Andrea Corcoran on recent calls

“As Jonay mentioned in her introductory remarks, earlier today, we issued a press release containing our financial results for the third quarter of 2026. The Statement of Operations and Balance Sheet are on Slides 28 and 29.”
CFO, Third Quarter 2026 Financial Results Conference Call ·
“As Jornay mentioned in her introductory remarks, earlier today we issued a press release containing our financial results for the first quarter of 2026. The Statement of Operations and Balance Sheet are on Slides 26 and 27.”
CFO, Atea Pharmaceuticals, Inc. Q1 FY2026 Earnings Call ·
“As Jornay mentioned in her introductory remarks, earlier today we issued a press release containing our financial results for the fourth quarter and full year 2025.”
CFO, Atea Pharmaceuticals, Inc. Q4 FY2025 Earnings Call ·
“As Jonay mentioned in her introductory remarks, earlier today we issued a press release containing our financial results for the third quarter of 2025. The statement of operations and balance sheet can be found on slides 24 and 25.”
CFO, Atea Pharmaceuticals, Inc. Q3 FY2025 Earnings Call ·
“As Jonea mentioned, earlier today we issued a press release containing our financial results for the second quarter of 2025. The Statement of Operations and Balance Sheet are on Slides 23 and 24.”
CFO, Atea Pharmaceuticals, Inc. Q2 FY2025 Earnings Call ·

Affiliation history

Company network

Leadership on record at Atea Pharmaceuticals, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Atea Pharmaceuticals, Inc. (AVIR) $549,530 $1,690,428
2024 Atea Pharmaceuticals, Inc. (AVIR) $533,524 $1,931,832
2023 Atea Pharmaceuticals, Inc. (AVIR) $517,984 $1,961,524
2022 Atea Pharmaceuticals, Inc. (AVIR) $493,319 $1,959,897
2021 Atea Pharmaceuticals, Inc. (AVIR) $478,950 $8,357,169
2020 Atea Pharmaceuticals, Inc. (AVIR) $465,000 $1,488,000
2019 Atea Pharmaceuticals, Inc. (AVIR) $290,000 $440,324

Recent activity

Show 9 earlier activities